Clinical Trials Logo

Carcinoma, Non-Small-Cell Lung clinical trials

View clinical trials related to Carcinoma, Non-Small-Cell Lung.

Filter by:
  • Suspended  
  • Page 1 ·  Next »

NCT ID: NCT06124118 Suspended - Clinical trials for Non Small Cell Lung Cancer

Tumor Treating Fields for Locally Advanced NSCLC

NOVOCURE
Start date: November 3, 2023
Phase: Phase 1
Study type: Interventional

The goal of this open-label, Phase 1 clinical trial is to determine the safety of TTFields started concurrently with SOC chemoradiation and during consolidation durvalumab in locally advanced, unresectable stage III non-small cell lung cancer (NSCLC). The main question it aims to answer is, "What is the rate of dose-limiting toxicities (DLTs) with TTFields in addition to concurrent chemoradiation and consolidation durvalumab?" Step 1 - All participants will be screened and enrolled in Step 1 prior to SOC concurrent chemoradiation. - The purpose of the Step 1 Registration is to ensure that eligible participants are candidate for concurrent chemoradiation and do not have contraindications to TTF therapy or immunotherapy. - Starting Level: Participants in Device Duration Level 1 will receive standard of care concurrent chemoradiation following Step 1 Registration. - Escalation Level : Participants in Device Duration Level 2 will begin standard of care chemoradiation and treatment with TTFields following Step 1 Registration. Step 2 - All participants will complete Step 2 screening and enrollment prior to receiving treatment with durvalumab consolidation therapy and TTFields. - The purpose of the Step 2 registration is to ensure that eligible patients meet criteria for consolidation durvalumab after completion of CRT and do not have contraindications to TTF. therapy or immunotherapy.

NCT ID: NCT05617313 Suspended - Clinical trials for Non Small Cell Lung Cancer

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Start date: February 17, 2023
Phase: Phase 2
Study type: Interventional

This open-label, non-randomized Phase II trial is designed to assess the safety and tolerability of GT103 in combination with pembrolizumab in adult subjects with relapsed or refractory, metastatic NSCLC. The study will consist of a safety lead-in of 10-20 patients. A total of 50 patients will be treated with the combination at the safest dose of GT103 as determined in the safety lead-in. If 10 additional patients are enrolled to the dose level -1 then the maximum of 60 subjects may be accrued to this trial.

NCT ID: NCT05421936 Suspended - Clinical trials for Carcinoma, Non-Small-Cell Lung

Osimertinib for NSCLC With Uncommon EGFR Mutations

UNICORN
Start date: September 27, 2020
Phase:
Study type: Observational

This is a multi-center, retrospective study of ucEGFRmut (exon 20 insertions excluded) metastatic NSCLC osimertinib-treated as first EGFR inhibitor. RECIST and RANO-BM brain objective response rate (ORR) were evaluated by investigators. mPFS, mOS and mDOR were calculated from osimertinib initiation. Mutations found at resistance were collected.

NCT ID: NCT05412875 Suspended - Clinical trials for Head and Neck Squamous Cell Carcinoma

Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This clinical trial investigates the acceptability of electronic cigarettes (JUUL) for smoking cessation (quitting smoking) and the reduction of surgery-related complications in patients with newly diagnosed head, neck, or lung cancer. Smoking before surgery is associated with increased risk of complications during and after surgery. Electronic cigarettes are a type of special product that gives small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking. Stopping cigarette smoking before surgery may reduce the risk of complications during and after surgery in patients with head, neck, or lung cancer.

NCT ID: NCT05378763 Suspended - NSCLC Clinical Trials

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

PINNACLE
Start date: May 12, 2022
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to compare the progression-free survival (PFS) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) exon 20 mutations when treated with poziotinib versus docetaxel.

NCT ID: NCT04835025 Suspended - Clinical trials for Non Small Cell Lung Cancer

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

This is a Retrospective, Multicenter, Controlled Study to Evaluate Immunotherapy and Radiotherpay for Brain Lesions as a Potential Treatment for Patients with Brain Metastasis in non-small cell lung cancer

NCT ID: NCT03824327 Suspended - Clinical trials for Lung Non-Small Cell Carcinoma

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

Start date: February 7, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and how well papaverine hydrochloride and stereotactic radiation therapy body (SBRT) work in treating patients with non-small cell lung cancer. Papaverine hydrochloride may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving papaverine hydrochloride with SBRT may work in treating patients with non-small cell lung cancer.

NCT ID: NCT03425331 Suspended - Clinical trials for Non-small Cell Lung Cancer

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Start date: February 28, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying two immunotherapy drugs as a possible treatment for advanced non-small cell lung cancer (NSCLC). The drugs involved in this study are: - Ipilimumab - Nivolumab

NCT ID: NCT02991651 Suspended - Clinical trials for Lung Cancer, Nonsmall Cell

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Start date: May 2016
Phase: Phase 1
Study type: Interventional

Patient selection: a) Pathological confirmation of non-small cell lung cancer without activating EGFR mutations; b) Advanced stage disease (IV or IIIB with malignant effusion) with at least two prior chemotherapy regimens; c) No available curative therapy; d) Pregnant women are excluded; e) Informed consent. Pretreatment evaluation: a) Medical history and physical examination; b) Hepatic and renal function (bilirubin, aspartate aminotransaminase, creatinine); c) Preoperative staging evaluation including CT-chest or PET/CT scan; Treatment plan: Three dose levels of IRX4204 and erlotinib will be studied using intra-patient dose escalation for dose levels 1 and 2. These study agents will be administered orally until progression of disease, unacceptable toxicities, activation of a phase II study of the combination, or exhaustion of the IRX4204 drug supply. Evaluation on study: Adverse events will be graded on a scale of 0 to 5, using the Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0. Efficacy will be assessed using the RECIST v1.1 criteria based on CT-chest or PET/CT scan after 8 weeks of study treatment.

NCT ID: NCT02470065 Suspended - Clinical trials for Non Small Cell Lung Cancer

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.

REMNANT
Start date: January 2016
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early stage NSCLC will be randomized between ARM A: neoadjuvant afatinib followed by surgery and ARM B: immediate surgery with curative intent.